A-196 is a potent and selective inhibitor of the lysine-specific demethylase 1 (LSD1), an enzyme involved in epigenetic regulation of gene expression. Its primary application lies in cancer research, particularly in the study of leukemia and other hematological malignancies, where LSD1 is often overexpressed. By inhibiting LSD1, A-196 induces re-expression of silenced tumor suppressor genes and promotes differentiation of cancer cells, thereby suppressing tumor growth. It is widely used as a pharmacological tool in epigenetic studies to probe the role of LSD1 in cellular processes such as stem cell differentiation, cell cycle regulation, and chromatin remodeling. A-196 has shown synergistic effects when combined with other anticancer agents, including retinoic acid and histone deacetylase inhibitors, enhancing its potential in combination therapy strategies. Due to its ability to cross the blood-brain barrier, A-196 is also being explored in neurological research, particularly in models where epigenetic dysregulation contributes to neurodegenerative conditions or cognitive disorders. Its selectivity and potency make it a valuable compound for validating LSD1 as a therapeutic target in both oncology and neuroscience.